Look­ing to re­bound from re­jec­tion in TNBC, Mer­ck­'s Keytru­da pass­es a new kid­ney can­cer test

Keytru­da has long been a dom­i­nant force in bio­phar­ma, rack­ing up bil­lions in sales for Mer­ck and con­tin­u­ing to ex­pand in­to more and more types of can­cer. And com­ing on the heels of a rare CRL in triple-neg­a­tive breast can­cer, the drug took an­oth­er step to­ward a po­ten­tial next in­di­ca­tion.

Mer­ck’s block­buster met its pri­ma­ry end­point in a Phase III study look­ing at Keytru­da as an ad­ju­vant ther­a­py for pa­tients with re­nal cell car­ci­no­ma fol­low­ing sur­gi­cal re­moval of a kid­ney, the Big Phar­ma an­nounced. Com­pared with place­bo, Keytru­da demon­strat­ed a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in dis­ease-free sur­vival.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER